26 January 2020

Oncode researchers gain access to Organoid technology thanks to collaboration with KNAW

Thanks to an agreement between the Royal Netherlands Academy of Arts and Sciences (KNAW) and Oncode Institute, the organoid technology will become available to all 800+ cancer researchers that are part of Oncode. The KNAW collaborates with its institutional partner UMC Utrecht on organoid technology. Thanks to this agreement with Oncode, researchers receive a license to conduct research on organoids for the first time in the Netherlands.

Elize Brolsma

Growing and researching organoids is a technology developed by Oncode researcher Hans Clevers. Clevers works - among others - at the Hubrecht Institute (KNAW) and the UMC Utrecht and is a professor at Utrecht University. The KNAW manages the licenses for the use of this technology together with UMC Utrecht. For the quality of cancer research, it is a unique step that unlimited research for academic purposes is now possible. The use of organoids allows researchers to analyze tumor growth with limited amounts of tissue from patients, to investigate genetic instability and to test new drug combinations.

Angus Livingstone, Valorization Director at Oncode Institute, says: “We are particularly proud that all researchers that are part of Oncode Institute now have unlimited access to this promising technology. An important goal of Oncode is to bring research results from the lab to patients faster. This agreement with KNAW is a good example of how we make this possible."

Mieke Zaanen, Managing Director of the KNAW, adds: “Fantastic research is being done within the national research institutes of the KNAW, which often leads to results that have a great impact. Thanks to Oncode Institute, this technology is now becoming more widely available which can make a difference for large and small groups of patients."

Arno Hoes, vice-chair of the executive board of UMC Utrecht and dean of the medicine faculty: "We think it is very important that this technology developed in Utrecht is widely used and we are pleased with this agreement.”

Cancer researchers who are not affiliated with Oncode that are interested to use this technology can contact KNAW.

Intestinal organoid, credit: Joep Beumer, copyright Hubrecht Institute

Other News

Oncode Coverbeeld Q2 2021
Oncode Digital Magazine - April 2021
Welcome to the April edition of our digital magazine! Discover the latest interviews, science stories, latest updates and much more.
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
Lude and Michiel
Oncode Investigators Michiel Vermeulen and Lude Franke receive Vici grant
Oncode is proud to announce that Oncode Investigators Michiel Vermeulen (Radboudumc) and Lude Franke (UMCG) will both receive the Vici grant of 1.5 million euros from the Dutch Research Council (NWO).
Ecto org KRT14
First patient-derived organoid model for cervical cancer
Researchers from the group of Oncode Investigator Hans Clevers (Hubrecht Institute) developed the first patient-derived organoid model for cervical cancer. They also modelled the healthy human cervix using organoids. In close collaboration with the UMC Utrecht, Princess Máxima Center for pediatric oncology and the Netherlands Cancer Institute, the researchers used the organoid-based platform to study sexually transmitted infections for a herpes virus. The model can potentially also be used to study the human papillomavirus (HPV), which is one of the main causes of cervical cancer.